- Home
- BFST vs DNTH Comparison
BFST vs DNTH Comparison
Compare BFST & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFST
- DNTH
- Stock Information
- Founded
- BFST 2006
- DNTH 2015
- Country
- BFST United States
- DNTH United States
- Employees
- BFST N/A
- DNTH N/A
- Industry
- BFST Major Banks
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- BFST Finance
- DNTH Health Care
- Exchange
- BFST Nasdaq
- DNTH Nasdaq
- Market Cap
- BFST 724.9M
- DNTH 657.0M
- IPO Year
- BFST 2018
- DNTH N/A
- Fundamental
- Price
- BFST $23.79
- DNTH $17.39
- Analyst Decision
- BFST Buy
- DNTH Strong Buy
- Analyst Count
- BFST 2
- DNTH 8
- Target Price
- BFST $30.00
- DNTH $53.00
- AVG Volume (30 Days)
- BFST 81.9K
- DNTH 255.5K
- Earning Date
- BFST 07-24-2025
- DNTH 05-12-2025
- Dividend Yield
- BFST 2.35%
- DNTH N/A
- EPS Growth
- BFST N/A
- DNTH N/A
- EPS
- BFST 2.43
- DNTH N/A
- Revenue
- BFST $276,739,000.00
- DNTH $6,524,000.00
- Revenue This Year
- BFST $25.40
- DNTH N/A
- Revenue Next Year
- BFST $5.33
- DNTH N/A
- P/E Ratio
- BFST $9.79
- DNTH N/A
- Revenue Growth
- BFST 11.75
- DNTH 102.36
- 52 Week Low
- BFST $18.97
- DNTH $13.37
- 52 Week High
- BFST $30.30
- DNTH $32.27
- Technical
- Relative Strength Index (RSI)
- BFST 48.39
- DNTH 35.86
- Support Level
- BFST $23.25
- DNTH $17.40
- Resistance Level
- BFST $24.33
- DNTH $18.45
- Average True Range (ATR)
- BFST 0.54
- DNTH 1.21
- MACD
- BFST -0.06
- DNTH -0.22
- Stochastic Oscillator
- BFST 29.11
- DNTH 10.60
About BFST Business First Bancshares Inc.
Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.